0000000000299663

AUTHOR

Hélène Fontaine

showing 4 related works from this author

Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – …

2013

International audience; Background & AimsIn phase III trials, the safety profile of triple therapy (pegylated interferon/ribavirin with boceprevir or telaprevir) seems to be similar in HCV treatment-experienced cirrhotic and non-cirrhotic patients, but few cirrhotics were included. We report the week 16 safety and efficacy analysis in a cohort of compensated cirrhotics treated in the French Early Access Programme.Methods674 genotype 1 patients, prospectively included, received 48 weeks of triple therapy. The analysis is restricted to 497 patients reaching week 16.ResultsA high incidence of serious adverse events (40.0%), and of death and severe complications (severe infection or hepatic dec…

Liver CirrhosisMaleCirrhosisBlood transfusionmedicine.medical_treatment[SDV]Life Sciences [q-bio]Chronic hepatitis CGastroenterologyTelaprevirTelaprevirCohort Studieschemistry.chemical_compound0302 clinical medicinePegylated interferonMedicineProspective StudiesAged 80 and overBoceprevirMiddle AgedViral Load3. Good healthTreatment OutcomeCirrhosis030220 oncology & carcinogenesisCohort030211 gastroenterology & hepatologyDrug Therapy CombinationFemaleFranceSafetyOligopeptidesmedicine.drugAdultmedicine.medical_specialtySerine Proteinase InhibitorsProlineAntiviral Agents03 medical and health sciencesInternal medicineBoceprevirRibavirinHumansAdverse effectAgedHepatologybusiness.industryRibavirinInterferon-alphaHepatitis C Chronicmedicine.diseaseSurgeryTreatmentchemistrybusiness
researchProduct

Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. : Triple therapy in HCV geno…

2014

International audience; BACKGROUND & AIMS: We investigated the effectiveness of the protease inhibitors peginterferon and ribavirin in treatment-experienced patients with hepatitis C virus (HCV) genotype 1 infection and cirrhosis. METHODS: In the Compassionate Use of Protease Inhibitors in Viral C Cirrhosis study, 511 patients with HCV genotype 1 infection and compensated cirrhosis who did not respond to a prior course of peginterferon and ribavirin (44.3% relapsers or patients with viral breakthrough, 44.8% partial responders, and 8.0% null responders) were given either telaprevir (n = 299) or boceprevir (n = 212) for 48 weeks. We assessed percentages of patients with sustained viral respo…

Liver CirrhosisMaleCirrhosisComorbidityHepacivirusmedicine.disease_causeGastroenterologyPolyethylene GlycolsTelaprevirCohort Studieschemistry.chemical_compound0302 clinical medicinePegylated interferonboceprevirProspective StudiesTreatment FailureAged 80 and overGastroenterologyMiddle AgedRecombinant Proteins3. Good healthTreatment Outcome030220 oncology & carcinogenesisDrug Therapy CombinationFemale030211 gastroenterology & hepatologyOligopeptidesmedicine.drugAdultmedicine.medical_specialtyGenotypeProlineHepatitis C virusAntiviral Agents03 medical and health sciencesBoceprevirInternal medicineRibavirinmedicinechronic hepatitis CHumanstelaprevirAdverse effect[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular BiologyAgedHepatologybusiness.industrycirrhosisRibavirinInterferon-alphaOdds ratioHepatitis C Chronicmedicine.diseasechemistryMultivariate AnalysisImmunologybusinessFollow-Up StudiesGastroenterology
researchProduct

LO3 : Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the french observational cohort ANR…

2015

International audience; no abstract

medicine.medical_specialtyDaclatasvirHepatologySofosbuvir[ SDV ] Life Sciences [q-bio]business.industry[SDV]Life Sciences [q-bio]3. Good healthHcv genotype 1Internal medicineCohortMedicineObservational studybusinessComputingMilieux_MISCELLANEOUSmedicine.drug
researchProduct

Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment

2021

International audience; Background & aims: Based on platelets and liver stiffness measurements, the Baveno VI criteria (B6C), the expanded B6C (EB6C), and the ANTICIPATE score can be used to rule out varices needing treatment (VNT) in patients with compensated chronic liver disease. We aimed to improve these tests by including data on the ratio of platelets to liver stiffness.Methods: In a retrospective analysis of data from 10 study populations, collected from 2004 through 2018, we randomly assigned data from 2368 patients with chronic liver disease of different etiologies to a derivation population (n = 1579; 15.1% with VNT, 50.2% with viral hepatitis, 28.9% with nonalcoholic fatty liver …

Blood PlateletsLiver CirrhosisNoninvasive Diagnosismedicine.medical_specialtyCirrhosis[SDV]Life Sciences [q-bio]PopulationEsophageal and Gastric VaricesChronic liver diseaseSeverity of Illness IndexGastroenterologyEnd Stage Liver Disease03 medical and health sciencesLiver disease0302 clinical medicineModel for End-Stage Liver DiseaseEsophageal varicesInternal medicineNonalcoholic fatty liver diseasemedicineHumanseducationBaveno VI CriteriaRetrospective Studieseducation.field_of_studyHepatologybusiness.industryGastroenterologyRetrospective cohort studyPortal Hypertensionmedicine.disease3. Good healthMELDCirrhosis030220 oncology & carcinogenesisElasticity Imaging Techniques030211 gastroenterology & hepatologybusinessBaveno VI Criteria Blood Platelets Cirrhosis Elasticity Imaging Techniques End Stage Liver Disease Esophageal and Gastric Varices Humans Liver Cirrhosis MELD Noninvasive Diagnosis Portal Hypertension Retrospective Studies Severity of Illness Index
researchProduct